Keyword: Vivus

Touting an off-label use is a big no-no in pharma marketing, and that's exactly what's landed Metuchen Pharmaceuticals in trouble with the FDA.

In their second enforcement letter of 2019, the FDA's marketing overseers reprimanded Vivus for downplaying the risks of its weight loss drug Qsymia.

With Pancreaze, a drug for CF patients, Vivus is stepping into an unfamiliar market. So it sponsored a fundraising event to get its name out.

Novo Nordisk is about to take on a task that’s so far foiled its peers: expanding the global obesity market.

Sanofi has seen enough of ED med Stendra, and it's walking away from its marketing partnership with maker Vivus.

Orexigen lost its Contrave marketing partner Takeda last month. Now, the drugmaker has terminated its second try at an FDA-mandated heart safety study, putting the drug at risk of FDA action.

@FiercePharma: FDA nixes Endo petition to protect Opana ER from generics. Article | Follow @FiercePharma > Irish drugmaker Elan ($ELN) snapped up a 21% share of Theravance ($THRX) royalties on a...